Technische Universität München
A protein causes higher risk of severe cancer progression for men
TECHNICAL UNIVERSITY OF MUNICH
Corporate Communications Center
Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de
This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/36939
High resolution images: https://mediatum.ub.tum.de/1631416
NEWS RELEASE
Cause found for higher sex-specific risk of mortality
A protein causes significantly higher risk of severe cancer progression for men
A remarkable number of life-threatening diseases manifest more severely in males than in females. One current example is COVID-19 caused by SARS CoV-2. Another example is the significantly higher risk of severe cancer progression for men. A research team at the Technical University of Munich (TUM) has now discovered a molecular cause for this difference between sexes.
Compared to women, men have a higher risk of experiencing severe progression of life-threatening diseases such as cancer. For example in Germany, every year over 130,000 male patients die of cancer as compared to only 100,000 female patients. According to the National Cancer Institute (USA) the cancer mortality rate in the US is 189.5 per 100,000 for men but only 135.7 per 100,000 for women.
Comprehensive epidemiological studies conducted in recent years have shown that the increased risk of men experiencing a more severe course of cancer is not exclusively based on a higher-risk lifestyle, such as a higher average consumption of tobacco or alcohol.
Thus, life-style-independent factors have to play a role, making it all the more important to identify parameters which cause the sex-specific course of the disease. This in turn might serve as a basis for improving decision-making and approaches of treatment.
A protein is the cause
A research team led by Prof. Achim Krüger at TUM’s university hospital Klinikum rechts der Isar has now identified the protein TIMP1 as a factor, which could explain this sex-specific difference and also improve the risk-diagnostics for the clinical course of the disease. The work was funded by the Wilhelm Sander Foundation, among other sources.
Based on patient cohorts from Germany and Canada, the research team found that men, whose blood contained a higher concentration of the endogenous protein TIMP1 also have a significantly higher risk of dying from cancer.
Further analyses then showed that the increase in TIMP1 causes increased liver metastasis, resulting in death in cases of pancreatic cancer, colon cancer, and melanoma.
Increased values indicate higher risk
"TIMP1 is not higher in all males, but the discovery of TIMP1 as a risk parameter, which can be identified in blood, now allows clinicians to identify the very group of men exhibiting a higher risk of developing life-threatening liver metastases," says Krüger.
"Previous studies have already shown the molecular context in which TIMP1 promotes liver metastasis," he adds. "In connection with our current discovery, there are now new possibilities for personalized medicine with optimized diagnosis and targeted therapy options."
In a next step Achim Krüger and his working group plan to further investigate the molecular causes of male-specific modifications in increased production of TIMP1 in the body.
Publikation:
C. D. Hermann, B. Schoeps, C. Eckfeld, E. Munkhbaatar, L. Kniep, O. Prokopchuk, N. Wirges, K. Steiger, D. Häußler, P. Knolle, E. Poulton, R. Khokha, B. T. Grünwald, I. E. Demir, A. Krüger
TIMP1 expression underlies sex disparity in liver metastasis and survival in pancreatic cancer
J Exp Med., Nov 1, 2021; 218(11):e20210911 (Online: Sep 17, 2021) – DOI: 10.1084/jem.20210911
More information:
The Wilhelm Sander Foundation, whose stated objective is the promotion of medical research, in particular of projects relating to the fight against cancer, supported the research project in two funding phases with a total of approximately 400,000 euros. In addition, the project received support from the German Research Foundation (DFG), die DZIF German Center for Infection Research, the Princess Margaret Cancer Foundation, the European Molecular Biology Organization (EMBO) and the Alexander von Humboldt Foundation.
In addition to several groups at the university hospital TUM Klinikum rechts der Isar, scientists of Toronto's University Health Network Princess Margaret Cancer Centre and of the University of Toronto Department of Medical Biophysics were also involved in the research activities.
High resolution images:
https://mediatum.ub.tum.de/1631416
Contact:
Prof. Dr. Achim Krüger
Technical University of Munich, Klinikum rechts der Isar
Institute of Molecular Immunology and Experimental Oncology
Ismaninger Str. 22, 81675 Munich, Germany
Tel.: +49 89 4140 4463 – E-Mail: achim.krueger@tum.de
Web: www.imi-muenchen.de/research-groups/krueger/research-group-krueger
Henrike Boden
Wilhelm Sander-Stiftung
Presse- und Öffentlichkeitsarbeit & Stiftungskommunikation
Tel.: +49 (0) 89 544187-0 – E-Mail: boden@sanst.de
Web: www.wilhelm-sander-stiftung.de
The Wilhelm Sander Foundation supported the research project in two funding periods with a total of approximately 400,000 euros. The Foundation's stated objective is the promotion of medical research, in particular of projects relating to the fight of cancer. Since its inception, the Foundation has contributed a total of more than 250 million euros towards the promotion of research in Germany and Switzerland. This has made the Wilhelm Sander Foundation one of the most important private research foundations in German-speaking countries. It was founded from the entrepreneur Wilhelm Sander’s bequest, who passed away in 1973. The Technical University of Munich (TUM) is one of Europe’s leading research universities, with more than 600 professors, 45,000 students, and 10,000 academic and non-academic staff. Its focus areas are the engineering sciences, natural sciences, life sciences and medicine, combined with economic and social sciences. TUM acts as an entrepreneurial university that promotes talents and creates value for society. In that it profits from having strong partners in science and industry. It is represented worldwide with the TUM Asia campus in Singapore as well as offices in Beijing, Brussels, Mumbai, San Francisco, and São Paulo. Nobel Prize winners and inventors such as Rudolf Diesel, Carl von Linde, and Rudolf Mößbauer have done research at TUM. In 2006, 2012, and 2019 it won recognition as a German "Excellence University." In international rankings, TUM regularly places among the best universities in Germany. www.tum.de